MedTrace Logo

Determination of Carboplatin's Optimal Plasmatic Exposure

NCT00145028 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2009-03-18

No results posted yet for this study

Summary

To determine Carboplatin's optimal exposures(optimal AUCs)and parameters they depend on.

Conditions

  • Neoplasms

Interventions

DRUG

Carboplatin

Sponsors & Collaborators

  • Institut Claudius Regaud

    lead OTHER

Principal Investigators

  • Laurence GLADIEFF, Doctor · Institut Claudius Regaud

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2007-12-31
Completion
2009-02-28

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00145028 on ClinicalTrials.gov